Allergy Therapeutics (LON:AGY) Sets New 1-Year Low – What’s Next?

Allergy Therapeutics plc (LON:AGY) reached a new 52-week low during trading on Tuesday . The company traded as low as GBX 6 and last traded at GBX 6.38, with a volume of 398951 shares changing hands. The stock had previously closed at GBX 6.82.

Allergy Therapeutics Stock Down 6.4%

The firm has a market cap of £404.33 million, a PE ratio of -6.58, a price-to-earnings-growth ratio of -30.70 and a beta of 0.87. The company has a quick ratio of 1.48, a current ratio of 1.13 and a debt-to-equity ratio of 629.58. The business has a 50-day moving average price of GBX 8.72 and a two-hundred day moving average price of GBX 10.22.

Allergy Therapeutics Company Profile

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.